CYTOKINETICS INC 4

Director John T. Henderson received a fully vested equity retainer grant of 272 shares of Cytokinetics, Inc. common stock, increasing his direct holdings to 78,360 shares, with an additional 83 shares held indirectly by his spouse.

On July 15, 2026, Dr. John T. Henderson of Cytokinetics, Inc. received a fully vested grant of 272 shares of Cytokinetics common stock under the company’s Equity in Lieu of Cash Retainer Program at an indicated price of $82.62 per share, representing compensation in stock instead of cash. This award, valued at approximately $22,460, increased his direct beneficial ownership to 78,360 shares. The Form 4 also notes an additional 83 shares of common stock held indirectly through his spouse, indicating a small related holding reported as indirect ownership. The transaction is a routine compensation-related stock award rather than an open-market purchase or sale and does not appear to reflect an active trading decision by the insider.

Filing Facts

CIK

1061983

Ticker

CYTK

Form

4

Source Type

fda

Accession

0001061983-26-000080

Alert Tier

5